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ABSTRACT 
Lung cancer, mostly non-small cell carcinoma 
(NSCLC), is still a major global problem with 
devastating outcomes. The majority presents at 
late stages, in which the chance of cure is 
minimal. With the better understanding of lung 
cancer biology, there have been several novel 
targeted approaches against NSCLC. Anti-an-
giogenesis has been proven to be an important 
approach in combination with systemic chemo-
therapy treatment in NSCLC at the first-line set-
ting. The prototypic monoclonal antibody against 
vascular endothelial growth factor (VEGF), be- 
vacizumab, is now approved for clinical use in 
combination with platinum-based chemotherapy 
in first-line treatment of advanced non-squamous 
NSCLC, associated with improved response and 
survival compared with chemotherapy alone. 
The most notable example of targeted therapy 
for lung cancer is epidermal growth factor re-
ceptor tyrosine kinase inhibitors (EGFR TKI). 
There have been extensive evidences support-
ing the superiority of EGFR TKI (like gefitinib or 
erlotinib) over standard platinum-based doublet 
chemotherapy in first-line treatment of advanced 
NSCLC carrying EGFR activating mutations. Al-
most following the same path as EGFR TKI, a 
novel target (anaplastic lymphoma kinase, ALK) 
has been identified recently with a very promis-
ing targeted agent (crizotinib) that has already 
been approved for clinical use in NSCLC carry-
ing ALK rearrangements. Over the past decade, 
there have been undoubtedly growing arma-
mentaria in the treatment of NSCLC, focusing on 
personalized and targeted approach. 
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1. INTRODUCTION 
Lung cancer has remained the top cancer killer 
worldwide over the past decade, and is expected to be so 
in the coming years. According to data from World 
Health Organization, lung cancer accounted for 1.38 mil-
lion deaths globally in 2008 (http://www.who.int/en/, last 
accessed on 10 June 2012). The overall prognosis is still 
poor with an overall 5-year survival around 15% only. 
The majority of lung cancer is histologically non-small 
cell carcinoma (NSCLC), with increasing predominance 
of adenocarcinoma. Apart from the lack of effective lung 
cancer screening in the past, the overall poor prognosis is 
mainly related to suboptimal treatment outcome for ad-
vanced or metastatic disease. With the advances in lung 
cancer biology, the complicated genetics and molecular 
pathogenetic pathways of lung cancer have been much 
better elucidated. In the past decade, there have been 
major landmark developments in targeted treatment for 
NSCLC, resulting in major change in the treatment para-
digm. The purpose of this short review is to highlight the 
recent advances in targeted therapy for NSCLC, namely 
anti-angiogenesis, anti-epidermal growth factor receptor 
(EGFR) and more recently inhibition of anaplastic lym-
phoma kinase (ALK). 
2. ANTI-ANGIOGENESIS 
It has been suggested that malignant tumours could 
not grow beyond 2 mm in size without efficient blood 
supply. [1] The occurrence of neovascularization would 
also enable migration of tumour cells through systemic 
circulation and subsequent development of distant me-
tastases. In fact, tumours remain dormant and unable to 
metastasize in the absence of a functional vascular supply. 
[2,3] The process of angiogenesis is mostly controlled by 
a balance between proangiogenic and antiangiogenic 
factors [4]. The most important proangiogenic factor 
involved in tumour angiogenesis, like in NSCLC, is vas-
cular endothelial growth factor (VEGF) [5]. Common 
approaches to inhibit VEGF pathway include agents that 
target VEGF or VEGF receptors. Prototypically, bevaci-
zumab is an anti-VEGF recombinant humanized mono- 
clonal antibody (93% human immunoglobulin G1 frame- 
work and 7% murine VEGF-binding complementarity- 
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determining regions), that prevents VEGF from binding 
its receptors and thus abrogating downstream biologic 
activities. 
Initial phase II trial of first-line combination of be- 
vacizumab and systemic chemotherapy (carboplatin/pac- 
litaxel) versus chemotherapy alone in advanced NSCLC 
has demonstrated superior response rate, time to progres-
sion and survival in the bevacizumab combination arm, 
with increased risk of life-threatening haemoptysis in 
squamous cell carcinoma. [6] Subsequent landmark ran-
domized phase III study (E4599) was conducted com-
paring the combination of bevacizumab with chemo-
therapy (carboplatin and paclitaxel) versus chemotherapy 
alone in the treatment of advanced chemonaive non- 
squamous NSCLC. [7] The findings confirmed a statisti-
cally significant survival advantage favouring bevacizu-
mab combination arm (median survival 12.3 months vs 
10.3 months in bevacizumab/chemotherapy vs chemo-
therapy alone arms, hazard ratio for death 0.79, p = 
0.003). The most notable toxicities in bevacizumab/ 
chemotherapy versus chemotherapy alone arms were 
grade 3/4 neutropenia (25.5% vs 16.8%), grade 3/4 hy-
pertension (7% vs 0.7%), grade 3/4 proteinuria (3.1% vs 
0%) and grade 3/4 haemorrhage (4.4% vs 0.7%). There 
were 17 treatment-related deaths (15 in bevacizumab/ 
chemotherapy arm and 2 in chemotherapy alone arm), in 
which all 5 deaths due to haemoptysis were exclusively 
from the bevacizumab/chemotherapy arm. This is the 
first proof-of-principle study to demonstrate superiority 
in combining targeted therapy with chemotherapy com-
pared to standard chemotherapy alone in the first-line 
treatment of patients with advanced NSCLC. Following 
this, the combination of bevacizumab, gemcitabine and 
cisplatin was also investigated in advanced NSCLC (AVAiL 
study), with favourable progression-free survival in the 
bevacizumab/chemotherapy arm compared to chemo-
therapy alone [8]. The safety of this approach of com-
bining bevacizumab with various first-line systemic che- 
motherapy regimens has been further confirmed and ex-
panded in phase IV clinical studies to include elderly 
population and brain metastases [9]. However, there is 
still a need for reliable predictive biomarkers that may 
help to identify those who would benefit most. 
3. ANTI-EPIDERMAL GROWTH FACTOR 
RECEPTOR (EGFR) 
Targeting specific and critical pathways that are essen-
tial for the survival of lung cancer can achieve specific 
tumour cell killing without much bystander damage to 
normal tissues. The first and well-established example 
for lung cancer is undoubtedly related to inhibition of 
EGFR. Functioning as a receptor tyrosine kinase, EGFR 
orchestrates a series of downstream signaling pathway 
that regulates tumour cell proliferation, invasion, angio-
genesis, metastasis, and apoptosis. Since over-expression 
of EGFR is commonly found in NSCLC, research has 
been focused on inhibiting EGFR pathway as an impor-
tant line of treatment. In general, the approaches to 
EGFR inhibition can be attained through either mono-
clonal antibody that targets the extra cellular binding site, 
or small molecules that target the intracellular adenosine 
triphosphate (ATP) binding site. 
Gefitinib was the first EGFR tyrosine kinase inhibitor 
(TKI) approved for use in the treatment of advanced 
NSCLC. Previous large-scale phase III trials (INTACT 1 
and 2) failed to demonstrate clinical benefit by combin-
ing gefitinib with platinum-based chemotherapy in first- 
line treatment of advanced NSCLC [10,11]. It was ap-
proved at the turn of this millennium for second-line 
treatment of advanced NSCLC mainly based on two 
phase II trials (IDEAL 1 and 2) of gefitinib monotherapy, 
without a placebo arm, in previously treated patients with 
advanced NSCLC [12,13]. The most common adverse 
effects were skin rash, diarrhea, and rarely interstitial 
pneumonitis. A subsequent randomized, placebo-con- 
trolled, phase III study (ISEL) on gefitinib versus pla-
cebo in relapsed advanced NSCLC demonstrated insig-
nificant improvement in survival (median survival 5.6 vs 
5.1 months in gefitinib vs placebo), despite some benefit 
among never smokers and patients of Asian descent [14]. 
Erlotinib is another EGFR TKI that has also been ex-
tensively studied in treatment of NSCLC. Similarly, 
large-scale phase III trials (TALENT and TRIBUTE) 
showed no clinical benefit in adding erlotinib to standard 
platinum-based chemotherapy as first-line treatment of 
advanced NSCLC. [15] A randomized, placebo-con- 
trolled, phase III trial of erlotinib versus placebo in 
treatment of advanced NSCLC after failure to previous 
chemotherapy showed superior response rate (8.9% vs 
1%), progression-free survival (2.2 vs 1.8 months) and 
overall survival (6.7 vs 4.7 months) in favour of erlotinib 
compared to placebo.[16] The more frequent adverse 
effects associated with erlotinib treatment were skin rash 
(76% vs 17%), anorexia (69% vs 56%), stomatitis (19% 
vs 3%), diarrhoea (55% vs 19%), ocular toxic effect 
(28% vs 9%) and infection (34% vs 21%) compared to 
placebo. 
Based on previous studies of gefitinib and erlotinib in 
NSCLC, several clinical and molecular predicting factors 
for response to treatment were widely observed. [17] 
Activating mutations in the EGFR tyrosine kinase do-
main (commonly deletion in exon 19 and L858R in exon 
21) have been shown to be associated with treatment 
response, while other mutations (like T790M in exon 20) 
might predict drug resistance. Interestingly, activating 
EGFR mutations predictive of EGFR TKI sensitivity are 
more prevalent in females, Asians, never smokers, and 
adenocarcinoma. These predictive clinico-epidemiological  
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factors have been previously used as the selection criteria 
for EGFR TKI treatment. The overall picture has become 
much clearer with the recent reports of several first-line 
clinical trials of EGFR TKI in NSCLC carrying activat-
ing EGFR mutations [18,19]. The first landmark phase 
III clinical trial (IPASS study) was conducted to investi-
gate the role of first-line gefitinib compared with stan-
dard chemotherapy (paclitaxel and carboplatin) in an epi- 
demiologically enriched population of advanced NSCLC 
(adenocarcinoma, neversmokers or former light smokers, 
Asians) [18]. Importantly, It was found that only around 
60% of tumours carried EGFR mutations in this clini-
cally enriched population. In the subgroup of tumours 
with activating EGFR mutations, gefitinib demonstrated 
superior objective response rate (71.2% vs 47.3%) and 
progression-free survival (hazard ratio 0.48, 95% CI 0.36 - 
0.64) compared with standard chemotherapy. However, 
gefitinib fared worse in objective response rate (1.1% vs 
23.5%) and progression-free survival (hazard ratio 2.85, 
95% CI 2.05 - 3.98) compared with standard chemo-
therapy among tumours without EGFR mutations. These 
findings were subsequently confirmed with a Japanese 
study comparing first-line gefitinib versus paclitaxel/ 
carboplatin in advanced adenocarcinoma of lung carry-
ing EGFR mutations[19] and a first-line study comparing 
erlotinib with standard chemotherapy (gemcitabine and 
carboplatin) in NSCLC with EGFR mutations (OPTIMA 
study). [20] Based on these concurring data, it is crucial 
to have sufficient tumour tissues at diagnosis for mo-
lecular (especially EGFR mutation) testing, in order to 
guide the first-line use of EGFR TKI in advanced 
NSCLC. 
Very recently, a large phase III trial has been con-
ducted to investigate the role of afatinib (a selective ir-
reversible EGFR, ErbB2 and ErbB4 inhibitor) compared 
with pemetrexed/cisplatin in first-line treatment of EGFR 
mutated advanced adenocarcinoma of lung (LUX-Lung 
3). The just released data (at American Society of Clini-
cal Oncology meeting 2012) have suggested significant 
improvement in progression-free survival with afatinib 
compared with chemotherapy arm (median 13.6 vs 6.9 
months, HR = 0.47 [0.34 − 0.65]; p < 0.0001) in those 
carrying common activating mutations. 
4. TARGETING ANAPLASTIC  
LYMPHOMA KINASE 
Very much analogous to the development of EGFR 
targeting approach, it has been recently discovered that a 
novel oncogene (anaplastic lymphoma kinase (ALK) 
rearrangements, commonly EML4-ALK fusion) could be 
accountable for lung carcinogenesis in around 5%. [21] 
Interestingly, the occurrence of ALK rearrangements 
shares the same epidemiological or clinical preponder-
ance as in EGFR mutations (i.e. nevermokers, adenocar-
cinoma), but tends to be exclusively found in EGFR 
wild-type (i.e. lack of mutations). A recent phase I study 
has provided very promising evidence that a specific 
ALK inhibitor (crizotinib) could result in significant tu-
mour response among those NSCLC carrying the ALK 
rearrangements. [22] This has led to the expedited ap-
proval by US Food and Drug Administration in treatment 
of NSCLC with ALK rearrangements. Ongoing phase II 
and III clinical trials on crizotinib are underway to estab-
lish its role in management of this subgroup of NSCLC. 
5. CONCLUSIONS 
The era of targeted approach in management of ad-
vanced NSCLC has certainly begun over the past few 
years and the field is expected to be evolving rapidly in 
the near future. Lung cancer is no longer considered a 
homogeneous disease. Despite traditional classification 
based on histology, there is increasing clinical demand of 
tumour molecular profiling to allow logical choice of 
specific targeted treatment. Second-generation targeted 
agents and multi-targeted agents are currently tested in 
clinical trials, which will help to expand the existing ar-
mamentaria in the battle against lung cancer. 
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